

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



August 10, 2022

### Commercial Pharmacy Benefit Exclusion for Amvuttra™ and Skyrizi®

Effective September 1, 2022, the products listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Product Name
Amvuttra™ (vutrisiran) injection solution for subcutaneous use
Skyrizi® (risankizumab-rzaa) injection solution for intravenous (IV) use

#### Products Impacted

This applies to the commercial line of business.

#### Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.